ClinicalTrials.gg
RecruitingNCT06325644Updated Nov 3, 2026

Well-Formulated Ketogenic Diet Polycystic Kidney Disease

An interventional study of Ketogenic Diet and Ketone/Glucose Monitoring in Polycystic Kidney Disease, sponsored by Ohio State University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Ohio State University · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 32 studies in Polycystic Kidney Diseases with a site in United States — 9 open to participants now, 9 under way, 1 of them phase 3. Polycystic Kidney Diseases · United States.

Planned enrollment
13th of 21
20 · median 25
Started
2024
with 1 other
No phase
5 of 32
3 open now
Registered
30th of 32
by date

Among the 32 studies in Polycystic Kidney Diseases with a site in United States, this one is the 13th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2024, is one of 5 with no phase, and was the 30th registered.

Polycystic Kidney Diseases

59 studies on the registry are indexed under Polycystic Kidney Diseases; 12 are open to participants now.

Browse Polycystic Kidney Diseases studies →

Open to participants now

9 of the 32 studies in Polycystic Kidney Diseases with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 11 Polycystic Kidney Diseases studies recruiting now, 6 (55%) set no upper age limit and 5 (45%) stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Polycystic Kidney Diseases with a site in United States, or all of them as a file.
02

Study summary

This is a prospective study to determine ketogenic diet effect on htTKV, GFR, microalbuminuria. This is a single-center study of 20 patients with ADPKD and deemed high risk for progression to ESRD. This determined by combination of features of ADPKD and htTKV as assessed by prior computed tomography (CT) or MRI. Patients will be recruited from the Polycystic Kidney Disease (PKD) Clinic at Ohio State University Wexner Medical Center. Enrolled patients will have MRI for htTKV, urinary studies, blood tests at baseline, 6 months, and 52 weeks. Blood for GFR will be assessed three times over the course of the study including baseline, 6 months, and 1 year. Participants will follow ketogenic diet for 52 weeks. Investigatory diet team will manage the ketogenic diet.

03

Conditions studied

  • Polycystic Kidney Disease
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-65 years old
  • Diagnosis of ADPKD by imaging and/or genetic testing
  • ≥ 25 mg/dl
  • Patients at risk for rapid progression of ADPKD: Mayo Class 1C-1E along with any other high risk features including early decline in GFR, hypertension onset ≤ 35 years of age, urologic events ≤ 35 years of age, PKD 1 truncating mutation and PROPKD score of 4 or higher as determined by the treating physician
  • No changes of medications within the last three months.
  • Able to comply with dietary intervention
  • Ability to sign

Exclusion criteria

Exclusion Criteria:

  • Patients currently being treated with Tolvaptan
  • Diagnosed with diabetes.
  • Pregnancy
  • to MRI
  • Ketogenic diet within the last three months
  • Severe kidney disease with \< 25 mg/dl
  • Unable to purchase food for the diet intervention
  • Gastrointestinal disorders that will interfere with diet intervention
  • Chronic alcohol or drug abuse
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Ketogenic Diet

    The KD will follow general principles the investigators have described with the aim to achieve blood ketones \>0.5 mM, which will require most participants to consume \<50 g/day carbohydrate and \~1.5 g/kg reference weight protein. Fat will comprise the remaining calories with an emphasis on monounsaturated and saturated sources from whole foods.

    Other: Ketogenic Diet · Biological: Ketone/Glucose Monitoring · Biological: CGM/CKM · Biological: Blood Draw · Other: Body Composition · Other: Change in glomerular filtration rate (mg/mmol) via magnetic resonance imaging (MRI) .

Interventions

  • OtherKetogenic Diet

    The diet intervention will start after all baseline testing is complete

  • BiologicalKetone/Glucose Monitoring

    KetoMojo hand-held glucometer will be used daily to monitor dietary intervention adherence.

  • BiologicalCGM/CKM

    Continuous Ketone/Glucose Monitor will be applied at the start of Test Day 1. The sensor will be checked by the study team at each test day and will be removed and replaced by a fresh sensor at \~2- week intervals during the study. The sensor will be removed at the end of the final test day.

  • BiologicalBlood Draw

    Blood samples will be collected according to the schedule in Figure 1

  • OtherBody Composition

    DEXA Scanning will be done pre-, mid-, and post- intervention.

  • OtherChange in glomerular filtration rate (mg/mmol) via magnetic resonance imaging (MRI) .

    Changes in glomerular filtration rate will be assessed via magnetic resonance imagining conducted by trained professionals. MRI imaging analyses will determine cardiac function. Trained imaging professionals will analyze the images to determine overall change (mg/mmol).

06

What researchers measure

Primary outcomes

  1. Finger Stick Beta-Hydroxybutyrate

    changes in fasting ketone levels.

    Time frame: Up to ~ 52 Weeks

  2. Finger Stick Glucose

    changes in fasting glucose levels.

    Time frame: Up to ~ 52 Weeks

Secondary outcomes

  1. Blood Pressure

    Changes in both Systolic and Diastolic blood pressure will be measured at each lab visit (eg. Baseline, Week 6, and Week 12). Recording: The systolic and diastolic pressures are recorded in millimeters of mercury (mmHg). For example, a reading of "120/80 mmHg" indicates a systolic pressure of 120 mmHg and a diastolic pressure of 80 mmHg.

    Time frame: Time Frame: Up to ~ 12 Weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2024
First posted
Mar 22, 2024
StartActual
Jun 1, 2024
Primary completionEst.
Dec 1, 2026
CompletionEst.
Apr 1, 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06325644
Responsible party
Sponsor
First posted
Mar 22, 2024
Start date
Jun 1, 2024
Primary completion
Dec 1, 2026 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Madison L Kackley, PhD
Contact
kackley.19@osu.edu
6142479650
Jeff Volek, PhD
Contact
volek.1@osu.edu
6142926488

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion